Core Biogenesis

Executive Summary

Core Biogenesis is a French biotechnology company founded in 2020 that has developed a novel platform using plants as biofactories to produce high-value recombinant proteins and peptides. By targeting these proteins to plant oleosomes, the company achieves enhanced stability and yield, offering a sustainable and scalable alternative to traditional mammalian or microbial production systems. Core Biogenesis focuses on enabling regenerative medicine and longevity skincare, positioning itself at the intersection of biomanufacturing and therapeutics. The platform's potential for low cost, high scalability, and reduced environmental impact makes it an attractive partner for companies seeking recombinant proteins for cell therapy, wound healing, or cosmetic applications. While still in early stages, Core Biogenesis is poised to capitalize on the growing demand for sustainable bioproduction in the biopharma and skincare industries. The company's plant-based expression system could disrupt traditional recombinant protein manufacturing by offering faster development timelines and lower capital expenditure. Key near-term milestones include securing series A funding, establishing commercial partnerships, and advancing its lead protein candidates toward preclinical validation. With a strong focus on regenerative medicine, Core Biogenesis aligns with the broader trend toward plant-derived biologics and sustainability in biotech.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026First Commercial Partnership for Recombinant Protein Supply60% success
• Q1 2027Lead Candidate Enters Preclinical Development50% success